| MRI-targeted or standard biopsy for prostate-cancer diagnosis V Kasivisvanathan, AS Rannikko, M Borghi, V Panebianco, LA Mynderse, ... New England Journal of Medicine 378 (19), 1767-1777, 2018 | 3644 | 2018 |
| Apalutamide treatment and metastasis-free survival in prostate cancer MR Smith, F Saad, S Chowdhury, S Oudard, BA Hadaschik, JN Graff, ... New England Journal of Medicine 378 (15), 1408-1418, 2018 | 1633 | 2018 |
| The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer A Afshar-Oromieh, E Avtzi, FL Giesel, T Holland-Letz, HG Linhart, M Eder, ... European journal of nuclear medicine and molecular imaging 42 (2), 197-209, 2015 | 1190 | 2015 |
| Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer A Afshar-Oromieh, CM Zechmann, A Malcher, M Eder, M Eisenhut, ... European journal of nuclear medicine and molecular imaging 41 (1), 11-20, 2014 | 1142 | 2014 |
| PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions A Afshar-Oromieh, A Malcher, M Eder, M Eisenhut, HG Linhart, ... European journal of nuclear medicine and molecular imaging 40 (4), 486-495, 2013 | 1129 | 2013 |
| F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients FL Giesel, B Hadaschik, J Cardinale, J Radtke, M Vinsensia, W Lehnert, ... European journal of nuclear medicine and molecular imaging 44 (4), 678-688, 2017 | 713 | 2017 |
| Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT M Eiber, K Herrmann, J Calais, B Hadaschik, FL Giesel, M Hartenbach, ... Journal of Nuclear Medicine 59 (3), 469-478, 2018 | 681 | 2018 |
| Detection of clinically significant prostate cancer using magnetic resonance imaging–ultrasound fusion targeted biopsy: a systematic review M Valerio, I Donaldson, M Emberton, B Ehdaie, BA Hadaschik, LS Marks, ... European urology 68 (1), 8-19, 2015 | 585 | 2015 |
| Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group CM Moore, V Kasivisvanathan, S Eggener, M Emberton, JJ Fütterer, ... European urology 64 (4), 544-552, 2013 | 512 | 2013 |
| Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy CM Zechmann, A Afshar-Oromieh, T Armor, JB Stubbs, W Mier, ... European journal of nuclear medicine and molecular imaging 41 (7), 1280-1292, 2014 | 458 | 2014 |
| Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience A Afshar-Oromieh, U Haberkorn, HP Schlemmer, M Fenchel, M Eder, ... European journal of nuclear medicine and molecular imaging 41 (5), 887-897, 2014 | 398 | 2014 |
| Multiparametric magnetic resonance imaging (MRI) and MRI–transrectal ultrasound fusion biopsy for index tumor detection: correlation with radical prostatectomy specimen JP Radtke, C Schwab, MB Wolf, MT Freitag, CD Alt, C Kesch, ... European urology 70 (5), 846-853, 2016 | 350 | 2016 |
| Apalutamide and overall survival in prostate cancer MR Smith, F Saad, S Chowdhury, S Oudard, BA Hadaschik, JN Graff, ... European urology 79 (1), 150-158, 2021 | 326 | 2021 |
| Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer WP Fendler, M Weber, A Iravani, MS Hofman, J Calais, J Czernin, H Ilhan, ... Clinical Cancer Research 25 (24), 7448-7454, 2019 | 294 | 2019 |
| The value of PSA density in combination with PI-RADS™ for the accuracy of prostate cancer prediction FA Distler, JP Radtke, D Bonekamp, C Kesch, HP Schlemmer, ... The Journal of urology 198 (3), 575-582, 2017 | 286 | 2017 |
| Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2) R Seifert, L Emmett, SP Rowe, K Herrmann, B Hadaschik, J Calais, ... European Urology 83 (5), 405-412, 2023 | 256 | 2023 |
| Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study A Gafita, J Calais, TR Grogan, B Hadaschik, H Wang, M Weber, S Sandhu, ... The Lancet Oncology 22 (8), 1115-1125, 2021 | 256 | 2021 |
| Clinical relevance and suppressive capacity of human myeloid-derived suppressor cell subsets S Lang, K Bruderek, C Kaspar, B Höing, O Kanaan, N Dominas, ... Clinical Cancer Research 24 (19), 4834-4844, 2018 | 247 | 2018 |
| Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion … JP Radtke, TH Kuru, S Boxler, CD Alt, IV Popeneciu, C Huettenbrink, ... The Journal of urology 193 (1), 87-94, 2015 | 246 | 2015 |
| Radiomic machine learning for characterization of prostate lesions with MRI: comparison to ADC values D Bonekamp, S Kohl, M Wiesenfarth, P Schelb, JP Radtke, M Götz, ... Radiology 289 (1), 128-137, 2018 | 238 | 2018 |
